Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=331 Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Acute Otitis Media
Primary: Time to Cessation of Otorrhea — 7.69; 22; 3.75 days
Phase 3 N=234 Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
HIV Infections · Cytomegalovirus Retinitis
Primary: Mortality — 107; 127 participants
Phase 3 N=113 Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
Hepatitis C
Primary: Percentage of HCV Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) — 95.1 Percentage of…
Phase 3 N=2,259 Vitamin D/Calcium Polyp Prevention Study
Colorectal Cancer · Polyps · Adenomas
Primary: Colorectal Adenomas — 48.2; 44.9; 47.0; 45.7 percentage of subjects
Phase 3 N=534 Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 — -0.88; -1.20; -1.47 % HbA1c — p=<0.0001
Phase 3 N=225 Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving Ankylosing Spondylitis (ASAS) 40 Response at Week 12 — 32.38; 15.74 Percentage of participants — p=0.0062
Phase 3 N=66 Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophy, Duchenne · Ambulatory Care
Primary: Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52 — -8.84; -2.57 percentage
Phase 3 N=303 A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis
Dermatitis · Atopic
Primary: Change From Baseline in Pruritus Score — -0.669; -0.638 units on a scale
Phase 3 N=110 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder · Tic Disorder
Primary: Percentage of Participants With Adverse Events. — 76.4; 4.5; 3.6 Percentage of participants
Phase 3 N=267 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1) — -5.54; -5.42; -9.03 millimeter(s) of mercury (mmHg)
Phase 3 N=268 Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
Nocturia
Primary: Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period — -1; -1.21; -1.25; -1.47 nocturnal voids — p=0.0280
Phase 3 N=241 Improving Function in Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47
Phase 3 N=395 Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
Nocturia
Primary: Change From Baseline in Mean Number of Nocturnal Voids Averaged Over a 3-Month Period — -1.06; -0.973; -0.591; -1.4 nocturnal voids — p=<0.0001
Phase 3 N=374 A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) — 97; 47; 58; 49 Participants